GLB-001
Phase 1Small molecule
GLB-001 is one of 51 small molecule programs targeting Myeloid Malignancies. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
51 competitors in Myelodysplastic Syndromes
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cytosar
TevaApproved
Idamycin
PfizerApproved
Reblozyl
Bristol-Myers SquibbPhase 3
Evrenzo
AstellasPhase 3
Xospata
AstellasPhase 3
Rytelo
GGeron Corporation
Approved
Fludara
SanofiPhase 2
Venclexta
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GLB-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGluBio Therapeutics Inc.